Author

Jaroslaw Kierkus

EFFICACY AND SAFETY OF ADALIMUMAB IN PEDIATRIC PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS: RESULTS OF A RANDOMIZED-CONTROLLED PHASE 3 STUDY
EFFICACY AND SAFETY OF ADALIMUMAB IN PEDIATRIC PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS: RESULTS OF A RANDOMIZED-CONTROLLED PHASE 3 STUDY

Jaroslaw Kierkus  et al.

EVALUATION OF CLINICAL RELATIONSHIP BETWEEN FECAL CALPROTECTIN AND ENDOSCOPIC FINDINGS IN ULCERATIVE COLITIS PATIENTS TREATED WITH INFLIXIMAB (CT-P13) SUBCUTANEOUS AND INTRAVENOUS THERAPY: RESULTS FROM A MULTICENTER, RANDOMIZED, CONTROLLED PIVOTAL TRIAL
EVALUATION OF CLINICAL RELATIONSHIP BETWEEN FECAL CALPROTECTIN AND ENDOSCOPIC FINDINGS IN ULCERATIVE COLITIS PATIENTS TREATED WITH INFLIXIMAB (CT-P13) SUBCUTANEOUS AND INTRAVENOUS THERAPY: RESULTS FROM A MULTICENTER, RANDOMIZED, CONTROLLED PIVOTAL TRIAL

Jaroslaw Kierkus  et al.

EXPOSURE-RESPONSE RELATIONSHIP OF SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) IN PATIENTS WITH ACTIVE CROHN'S DISEASE AND ULCERATIVE COLITIS: ANALYSIS FROM A MULTICENTER, RANDOMIZED CONTROLLED PIVOTAL TRIAL
EXPOSURE-RESPONSE RELATIONSHIP OF SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) IN PATIENTS WITH ACTIVE CROHN'S DISEASE AND ULCERATIVE COLITIS: ANALYSIS FROM A MULTICENTER, RANDOMIZED CONTROLLED PIVOTAL TRIAL

Jaroslaw Kierkus  et al.

European Crohn’s and Colitis Organisation Topical Review on Transitional Care in Inflammatory Bowel Disease
European Crohn’s and Colitis Organisation Topical Review on Transitional Care in Inflammatory Bowel Disease

Jaroslaw Kierkus  et al.

EFFECT OF MIRIKIZUMAB ON INFLAMMATORY BIOMARKERS IN A PHASE 2 STUDY OF PATIENTS WITH CROHN'S DISEASE
EFFECT OF MIRIKIZUMAB ON INFLAMMATORY BIOMARKERS IN A PHASE 2 STUDY OF PATIENTS WITH CROHN'S DISEASE

Jaroslaw Kierkus  et al.

ECCO-ESCP Consensus on Surgery for Crohn’s Disease
ECCO-ESCP Consensus on Surgery for Crohn’s Disease

Jaroslaw Kierkus  et al.

Item 1 - 6 / 6
1